Alternatives to Schrodinger

Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

Owkin's K Pro is an autonomous AI scientist for drug discovery and clinical trial decisions, built on multimodal patient data

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Clinical-stage biotech designing highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Causal AI drug discovery that pairs 20+ petabytes of cellular data with human genetics to find real disease targets

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

Recursion's AI drug discovery platform pairing 2M weekly wet-lab experiments with a 50+ PB proprietary dataset, now incorporating Exscientia.

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Clinical-stage techbio company pairing automated wet labs with AI models to discover and develop drugs.

Iktos pairs generative AI for small-molecule design with AI retrosynthesis and robotic lab automation.

AI protein engineering platform that designs optimized variant plates and learns from every wet-lab round.

WhiteLab Genomics' ALFRED platform predicts and optimizes molecular constructs for gene and RNA therapies before synthesis

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

AI drug discovery from Isomorphic Labs: predictive and generative models that design molecules and forecast drug performance.

Silico is Goodfire's mechanistic interpretability agent for understanding, debugging, and steering the internals of your AI models.

Oncology real-world evidence built from point-of-care patient data, with AI-powered analysis layered on top.

All-in-human foundation models that read a routine blood draw to predict brain activity, therapy response, and side effects in neurology.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Benchling unifies ELN, LIMS, and AI agents for biotech R&D in one cloud platform.

FDA-cleared AI for cancer pathology on H&E slides, plus the Virchow and PRISM foundation models licensed to biopharma and researchers.

Quibim turns MRI, CT and PET scans into cleared, quantitative imaging biomarkers for prostate, brain, liver, breast and lung.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

Cellino builds the manufacturing layer for personalized cell therapy: AI-guided optical bioprocessing on its modular Nebula™ platform.

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.